Global WholeHealth Partners Corp (OTC

GWHP) Partners With Pan Probe Biotech and AvantGen to Develop the Newest COVID19 Antigen Test on the Market; 8k Filed on 09/21/2021

Global WholeHealth Partners Corp (GWHP) is confident in the new partnerships to produce the best COVID Antigen test on the market.

San Clemente, CA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- COVID Antigen testing is not going away and has become the new test and vaccine for years to come.  

Global WholeHealth Partners Corp. (OTC: GWHP) offers one of the largest lines of COVID 19 tests. Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.  The strains identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) strain contains multiple mutations, most reflected in the S gene, which encodes the spike protein. Global understands the need to be ahead of the virus to conquer the virus. Now, with the vaccine, Global is offering one of the largest lines of products to fight this virus.

Global understands that this is a war on COVID 19 and we are expanding our line of products to be able to fight. With a facility now in the Philippines, Global will be able to fight the COVID War better by taking the fight to some of the regions of the world which have not been serviced.

Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID. Global WholeHealth Partners knows that the quicker the test results can be reviewed by a Front-Line Healthcare Worker, the quicker we can stop the spread of this disease.

With results in minutes versus hours or days with other diagnostic kits, the more lives that can be saved with the only FDA authorized COVID-19 POC serology Point of Care Test. With the new fingerstick test, healthcare providers can prick a patient’s finger and get results in minutes without having to wait for venous blood. Global WholeHealth Partners will be able to distribute these tests to more urgent cares, hospitals, and – to help curb the spread of CoViD19 SARS2.

As a third surge of the coronavirus threatens much of the United States, public health experts across the country say there still aren’t enough tests available to keep the virus under control. With the continual mutation of the virus, Global is keeping up with demand and keeping up with the continual changes of the virus in the R & D of the tests.